Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Celleron Therapeutics, Oxford Cancer Biomarkers ; Afrox ; GlaxoSmithKline and Bayer HealthCare Pharmaceuticals Hello. I'm David Kerr, professor of cancer medicine from University of Oxford. I've had a long-term interest in the use of, both COX-1 and COX-2 inhibitors, to see what we can do to reduce incidence and improve mortality for patients with.
Here we have a plausible mechanistic insight as to how aspirin might have this role in reducing incidence and mortality of colorectal cancer. Most work has been pharmacologic and focused on the impact of aspirin on platelet function through various prostaglandin synthesizes and so on, looking, importantly and relevantly, at the anti-inflammatory properties.
This is a really nice paper that adds to the volume of work on aspirin that we're seeing coming through. Please have a look at it and tell me what you think. I think it was very well conducted. It's something which I hope that, using our own data, we will be able to look at and hopefully validate.